)
Corvus Pharmaceuticals (CRVS) investor relations material
Corvus Pharmaceuticals Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline and mechanism
Soquelitinib, an oral selective ITK inhibitor, is in a Phase III registrational trial for relapsed/refractory PTCL and a Phase II atopic dermatitis trial; both are enrolling.
ITK inhibition blocks Th2 and Th17 signaling while sparing RLK, preserving Th1 activity; the proposed effect is immune rebalancing, including increased active Tregs, rather than broad immune suppression.
Reported binding affinity was KD 6.5 for ITK versus 2,700 for RLK; selectivity is intended to limit off-target effects, and clinical safety was described as comparable to placebo.
IP protection extends through November 2037, or 2042 with pharmaceutical extensions; HS enrollment began, and an asthma study is planned for early 2027.
Atopic dermatitis findings
In a 72-patient Phase I monotherapy study, the higher-dose, 8-week cohort showed EASI-75 of 75% versus 20% on placebo and IGA 0/1 of 33%.
Across cohorts, active treatment separated from placebo as early as week 2; responses were also observed among patients with prior systemic therapy and treatment-resistant patients.
EASI-75 responses persisted after treatment ended: the first three cohorts remained near 40% at 90 days off treatment, while the higher-dose cohort maintained response at 30 days off treatment.
Biomarkers showed reductions in IL-4, IL-5, IL-13 and TARC, plus increased Tregs that remained elevated off treatment; safety was described as favorable and comparable to placebo.
SIERRA1 is enrolling 200 adults across four cohorts, testing 200 mg QD, 200 mg BID and 400 mg QD versus placebo; results are planned for Q3 2027.
Other programs and 2027 milestones
The Phase III PTCL trial has a futility analysis planned for Q1 2027 and top-line data expected by year-end 2027; the program has orphan drug and fast track designations.
A Phase I-B HS proof-of-concept trial is enrolling up to 25 patients for 12 weeks; safety, HiSCR, IHS4 and skin and blood biomarkers will be assessed, with data expected in H1 2027.
The asthma trial is planned to start in early Q1 2027 and enroll both T2 and non-T2 patients, with interim assessment by group; Angel plans to initiate a China asthma trial in Q2.
Angel Pharmaceuticals, 49%-owned, is running a China AD study: cohort one data are expected in March 2027, and cohort two data in H2 2027; the partner may expand enrollment by 60–90 patients after Phase I-B.
- Soquelitinib advances across indications; $202.9M funds operations into Q2 2028.CRVS
Q3 2026 - Oral ITK inhibitor soquelitinib targets multiple immune diseases with pivotal data expected by 2027.CRVS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Soquelitinib shows robust efficacy and safety in AD, supporting broad immune disease potential.CRVS
Corporate presentation - Q2 2026 net loss rose to $18M as R&D spending increased; cash runway extends into Q2 2028.CRVS
Q2 2026 - Lead asset soquelitinib advances in oncology and immunology with strong IP and cash runway.CRVS
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Durable efficacy and safety demonstrated in immune diseases, with broad clinical expansion underway.CRVS
Jefferies Global Healthcare Conference 2026 - Strong efficacy, safety, and immune modulation support Phase II trials for soquelitinib in atopic dermatitis.CRVS
Study result - Soquelitinib showed robust efficacy and safety, with $31.3M raised to fund operations into late 2026.CRVS
Q1 2025 - Soquelitinib advances with strong clinical data and a $52M cash runway into Q1 2026.CRVS
Q4 2024
)
)
)
)
)
)
)
)